Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POPRACH Alexandr FIALA Ondrej CHLOUPKOVÁ Renata MELICHAR Bohuslav LAKOMÝ Radek PETRÁKOVÁ Katarína ZEMANOVA Milada KOPECKOVA Katerina SLABÝ Ondřej STUDENTOVA Hana KOPECKY Jindrich KISS Igor FINEK Jindrich DUŠEK Ladislav BUCHLER Tomas

Year of publication 2018
Type Article in Periodical
Magazine / Source Anticancer Research
MU Faculty or unit

Faculty of Medicine

Citation
Web https://ar.iiarjournals.org/content/38/1/449.long
Doi http://dx.doi.org/10.21873/anticanres.12243
Keywords Renal cell carcinoma; pazopanib; response; survival; cancer registry
Description Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.